Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17681732 | 0.81 | PRKCI (0.49) | AXLPRKCINOTUMRHEBJAK2 | |
| SCHEMBL19463270 | 0.77 | AKR1B1 (0.40) | AKR1B1PTGS2JAK3CA2 | |
| SCHEMBL25258364 | 0.76 | AXL (0.47) | AXLPRKCINOTUMRHEBJAK2 | |
| SCHEMBL17681735 | 0.74 | PRKCI (0.45) | AXLPRKCIJAK2JAK1TYK2 | |
| SCHEMBL17671024 | 0.73 | AKR1B1 (0.50) | RHEBAKR1B1CA2 | |
| SCHEMBL29686671 | 0.73 | AKR1B1 (0.50) | RHEBAKR1B1CA2 | |
| SCHEMBL21121113 | 0.73 | AXL (0.41) | AXLPRKCINOTUMJAK2JAK1 | |
| SCHEMBL17681733 | 0.71 | AXL (0.43) | AXLPRKCIJAK2JAK1TYK2 | |
| SCHEMBL1356886 | 0.71 | PRKCI (0.67) | AXLPRKCIRHEBJAK2JAK1 | |
| SCHEMBL20862242 | 0.71 | PRKCI (0.45) | AXLPRKCIJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313677-A1 | Isoindoline Derivatives | OPRD1, ADRA1D, DRD2 | AXL 3348/4885PRKCI 1243/4885NOTUM 4576/4885 |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | AXL 2759/4885PRKCI 1550/4885NOTUM 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.